PBAC go-ahead for adrenaline nasal spray

PBS listing recommendation for neffy, with PBAC citing previous shortages of adrenaline auto-injector pens The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the listing of neffy nasal spray, for the emergency treatment of acute severe allergic reactions in children (over 4 years and 15 kg) or adults at significant risk of anaphylaxis. A new form